搜索结果：phytotherapy

There are currently no registered medicines available for the treatment of gambling disorder. To describe the evidence about medication for gambling disorder. We conducted a systematic review of the effectiveness of medication for gambling disorder in Medline, Embase, and PsycInfo. Due to methodological differences between the studies no meta-analysis could be performed. We included 24 double-blind, randomized trials with a total of 1,547 patients, analyzing the effect on gambling disorder of opioid antagonists, antidepressants, antipsychotics, mood stabilizers, anti-epileptics, glutamate modulators and phytotherapy. In 21 studies active medication was compared to placebo and in three studies two active medications were compared. Of the seven studies about opioid antagonists, four reported significantly better results than placebo. A positive effect was seen less frequently with the other drugs. Due to the limited evidence, only patients who do not respond to psychotherapeutic interventions might be considered for off-label treatment with an opioid antagonist such as naltrexone or nalmefene. For all other medications investigated, there is currently insufficient evidence of effectiveness in treating gambling disorder.

Phytotherapy has emerged as a promising strategy for the management of obesity and related metabolic disorders. In this context, species of the Physalis genus have been widely recognized in traditional medicine for their potential therapeutic effects against these conditions. This study aimed to evaluate the effects of Physalis philadelphica husk infusion on obesity and associated metabolic disturbances such as hyperglycemia, insulin resistance, hepatic steatosis, and oxidative stress markers in diet-induced obese rats. Male Wistar rats were allocated into three groups (n = 8): (1) healthy control, (2) obese control group, and (3) intervention group (husk infusion). Obesity was induced using a high-fructose and high-saturated fat diet (~511.1 kcal/100 g), followed by 16 weeks of husk infusion administration. After euthanasia, hyperglycemia, insulin resistance, hepatic steatosis, and oxidative stress markers were analyzed. Results showed that rats receiving the husk infusion exhibited a significant reduction in weight gain (~7.2%), serum glucose levels (22.8%), and free fatty acids (26%) compared to the obese control group, while no significant effects on insulin sensitivity, hepatic steatosis, or several lipid-related parameters were observed. Regarding oxidative stress markers, serum nitrite levels decreased by 33%, and malondialdehyde (MDA) levels in the liver (30%) and adipose tissue (38%) were significantly reduced compared to the obese control group. Moreover, treated rats showed a significant increase in catalase (~1.2-fold) and superoxide dismutase (~2.8-fold) activity in the liver. These findings suggest that Physalis philadelphica husk infusion reduces hyperglycemia and improves oxidative stress in obese rats.

Approaches to the treatment of cystitis have changed in recent years. Although the benefit of antibiotics in urinary tract infection is evident, excessive and inappropriate use has contributed to increased antimicrobial resistance among uropathogens and a higher rate of adverse events. Compared with placebo, clinical success of antibiotic therapy for cystitis is higher; however, in some cases the use of nutraceuticals, nonsteroidal anti-inflammatory drugs, and phytotherapy has made it possible to substantially reduce the frequency of antibiotic prescriptions. To evaluate the efficiency, safety, and tolerability of Superlymph rectal/vaginal suppositories in patients with chronic cystitis during exacerbation as monotherapy. This pilot open-label prospective non-comparative study included 30 female patients aged 20 to 49 years with chronic cystitis during exacerbation. All patients presented for the first time with frequency and painful urination (30/100%), dysuria with burning/pain on urination (22/73,3%), and blood drops from the urethra at the end of urination (7/23%). Disease duration did not exceed one day (mean 18,8+/-2,4 hours). Before seeking medical care, none of the patients had taken any medications. All patients refused antibiotics for different reasons: planned pregnancy in the near future; allergy or intolerance to antibacterial drugs; rapid development of bacterial vaginosis/vulvovaginal candidiasis or intestinal dysbiosis associated with prior antibacterial therapy. This refusal was confirmed by an official written refusal of antibacterial drugs within the study. All patients started therapy with a cytokine and antimicrobial peptide complex (Superlymph) as suppositories, administered rectally according to a two-stage regimen: during the intensive treatment phase lasting 20 days, Superlymph was prescribed at a dose of 25 IU daily; during the continuation phase, patients received 10 IU for 10 days. At baseline, the mean total score on the ACSS scale was 14,9+/-2,3, and all patients had leukocyturia. Urine culture revealed bacterial growth in 24 patients (80,0%). By the end of the intensive phase, the mean total score decreased to 6,2+/-0,9. By the end of the continuation phase, all patients felt well; dysuria was completely resolved, which accordingly improved quality of life. The mean total score at the end of treatment was 1,9+/-0,2. No cystitis recurrences occurred within three months; during six months, recurrence was recorded in 4 patients (13,3%). Superlymph monotherapy for chronic cystitis is highly effective and safe. Additional antibacterial therapy was required in only 13,3% of cases, while in 86,7% recurrence of chronic cystitis was controlled with Superlymph monotherapy. Three months after completion of therapy, none of the patients developed cystitis recurrence; within 6 months after completion of local cytokine therapy, recurrence occurred only in 4 patients (13,3%). No complications or adverse reactions during Superlymph therapy were observed.

The review evaluates current clinical and epidemiological evidence regarding the use of plant-derived compounds in pediatric practice. Data from randomized controlled trials indicate symptomatic efficacy of selected agents-particularly in acute respiratory infections-alongside generally favorable safety profiles when standardized preparations are used. Emerging research also explores applications in neurodevelopmental disorders, gastrointestinal conditions, and dermatology, and as supportive therapy in pediatric oncology. However, variability in product quality, limited pediatric-specific trials, potential toxicity, and regulatory inconsistencies remain significant challenges. The integration of phytotherapy into pediatric care therefore requires rigorous study design, careful safety monitoring, and clear quality standards to ensure an evidence-based risk-benefit balance.

Enzymatic nanomotors (EMNMs) represent an emerging class of intelligent nanosystems that exploit enzymatic biocatalysis to generate autonomous motion within biological environments, including complex cellular and tissue contexts within living organisms. Owing to their ability to utilize endogenous biofuels, high biocompatibility, and capacity for targeted propulsion, EMNMs have demonstrated considerable potential in diverse biomedical applications. These include targeted drug delivery, cancer therapy, diagnostics, and bioimaging, as well as the traversal of biological barriers. This review comprehensively discusses the mechanisms underlying enzyme-driven propulsion, nanomotor design strategies, and their current and prospective applications in medicine, while also addressing major challenges associated with enzymatic stability, biocompatibility, motion control, and clinical safety. Furthermore, future perspectives are highlighted, including enzyme cascade systems, intelligent nanomotor swarms, biodegradable materials, and strategies facilitating clinical translation. As a representative example of practical application, curcumin was employed as a model therapeutic agent due to its well-established anticancer, anti-inflammatory, and antioxidant properties, enabling evaluation of the nanomotors' capability for controlled, pH-responsive release of therapeutic cargo. Nanophytomedicine enhances the therapeutic efficacy of phytochemicals by improving their stability, bioavailability, and targeted delivery through nanocarrier systems. The integration of phytotherapy with nanotechnology offers promising opportunities for the development of safer and more effective therapeutic strategies.

The article considers placement of methods of traditional and complementary medicine in the public health system of the Russian Federation, focusing on prevention and management of chronic non-communicable diseases. The analysis of the evidence base on key methods of traditional and complementary medicine (acupuncture, phytotherapy, homeopathy, manual therapy, osteopathy) was carried out, including differentiated estimate of level of evidence for forms of homeopathy based on the latest systematic review of meta-analyses. The legal framework of its application in Russia are explored. The corresponding collisions and barriers are identified. The following proposals concerning integrative health care model are formulated: differentiated register of methods, clinical guidelines, pilot integration into compulsory health insurance system and enhancement of research. Рассмотрено место методов традиционной и комплементарной медицины в системе общественного здравья Российской Федерации с фокусом на профилактику и управление хроническими неинфекционными заболеваниями. Проведен анализ доказательной базы по ключевым методам традиционной и комплементарной медицины (акупунктура, фитотерапия, гомеопатия, мануальная терапия, остеопатия), включая дифференцированную оценку уровня доказательств для форм гомеопатии на основе новейшего систематического обзора метаанализов. Исследованы правовые рамки применения ее в России, выявлены коллизии и барьеры. На основе анализа сформулированы предложения по интегративной модели здравоохранения: дифференцированный реестр методов, клинические рекомендации, пилотная интеграция в ОМС и усиление исследований.

Background/Objectives: Filipendula ulmaria (L.) Maxim. (meadowsweet) is a medicinal plant traditionally used for its antioxidant and anti-inflammatory effects. There is also some data indicating its anticancer potential; however, its impact on colorectal cancer cells remains poorly understood. Here we investigated the cytotoxic and pro-apoptotic effects of an aqueous F. ulmaria extract on human LoVo colorectal cancer cells and analyzed some of the mechanisms underlying it. Methods: LoVo colorectal cancer cells were treated with the aqueous extract and analyzed for intracellular reactive oxygen species (ROS), mitochondrial membrane potential, DNA damage, lysosomal alterations, apoptosis-related mechanisms, and antioxidant activity. Phytochemical profiling was performed by HPLC-TOF/MS. Results: The extract elevated intracellular ROS levels, disrupted mitochondrial membrane potential, and induced DNA damage in LoVo cells. Activation of crucial caspases, along with increased p53 levels, confirmed engagement of both extrinsic and intrinsic apoptotic pathways. Changes in lysosomal fluorescence were also observed, indicating alterations in lysosomal properties. In chemical assays (FRAP, TAC, DPPH, ABTS, and superoxide scavenging), the extract demonstrated robust antioxidant capacity comparable to or exceeding that of ascorbic acid. Phytochemical profiling by HPLC-TOF/MS revealed a rich presence of bioactive flavonoids, phenolic acids, and coumarins. Altogether, our findings indicate that the extract's cytotoxicity against colon cancer cells arises from a multifaceted mechanism involving oxidative stress, organelle dysfunction, and apoptosis induction. Conclusions: These results highlight F. ulmaria aqueous extract as a promising candidate for colorectal cancer phytotherapy as a form of supportive treatment and warrant further preclinical validation.

Background/Objectives: Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes and remains associated with limited therapeutic options and high systemic toxicity from conventional chemotherapy. Ipomoea pes-caprae is a coastal medicinal plant traditionally consumed in Mexico for inflammatory and renal disorders and contains bioactive metabolites with reported antioxidant and pharmacological properties. However, its antitumoral activity and systemic safety profile remain poorly understood. This study aimed to characterize the phytochemical composition, antioxidant capacity, antitumoral activity, and toxicity of a traditionally prepared aqueous infusion of I. pes-caprae leaves (IPCAE). Methods: IPCAE was characterized using phytochemical screening and complementary instrumental analyses. Antioxidant activity was evaluated using the DPPH assay. A randomized preclinical study was performed in mice bearing MDA-MB-231 xenografts treated with IPCAE, cisplatin, or saline control. Results: The infusion showed measurable antioxidant activity (72.25 &#xb1; 1.25% DPPH inhibition at 1 mg/mL) and a total polyphenol content of 7.29 &#xb5;g/mg gallic acid equivalents. Phytochemical screening revealed abundant flavonoids and reducing sugars, with moderate saponin content. In vivo, IPCAE produced only a transient and non-significant trend toward slower tumor progression compared with control (p = 0.214) and cisplatin (p = 0.377). However, marked systemic toxicity was observed, including severe thoracic dermal lesions in 40% of animals and 70% mortality by day 15. Survival was significantly reduced compared with control and cisplatin groups (p < 0.001). Conclusions: Although IPCAE exhibited antioxidant activity, no statistically significant antitumoral effect was observed under the evaluated conditions. Furthermore, repeated oral administration resulted in marked systemic toxicity, characterized by visible dermal lesions, clinical deterioration, and increased mortality. Therefore, the present findings do not support the use of the evaluated crude preparation as an anticancer intervention. Future studies should focus on detailed toxicological characterization, bioassay-guided fractionation, dose optimization, and identification of the individual metabolites responsible for the observed biological effects. The antioxidant activity demonstrated in this study should be interpreted independently from antitumoral activity, as no causal relationship between these findings was established.

The rhubarb root and the senna leaf are two commonly used laxative herbs for functional constipation, containing dianthrones and free anthraquinones. As a free anthraquinone, emodin is a crucial constituent isolated from laxative botanicals, and it is particularly abundant in the rhubarb root, a key ingredient in the classic Chinese medicine formula MaZiRenWan (or herbal medicine CDD-2101). This study explored emodin's anti-malignancy, anti-inflammation, and underlying mechanisms. We examined emodin and other anthraquinones on human colorectal cancer cell proliferation, then used ApcMin/[Formula: see text] mice to assess effects on animal lifespan, intestinal tumor multiplicity, inflammatory cytokines, and adaptive immunity. Results showed MaZiRenWan extract inhibited HCT-116/HT-29 human cancer cells. However, two primary dianthrone sennosides, sennoside A and sennoside B, did not demonstrate such pronounced effects. Three free anthraquinones, emodin, aloe-emodin, and rhein, displayed antiproliferative effects on cancer cells, which were observed to be significantly concentration- and time-dependent, with emodin demonstrating the strongest action. Emodin was found to induce cell cycle arrest during the S-G2/M phases and trigger apoptosis. In vivo, emodin extended ApcMin/[Formula: see text] mice lifespan, reduced gut tumors, downregulated gut tissue levels of key pro-inflammatory cytokines such as IL-1&#x3b1;, IL-1&#x3b2;, IL-6, IL-17A, IL-8, G-CSF, and GM-CSF; this result was supported by the IL-8 secretion test. Emodin had no inhibitory effect on regulatory Treg cell differentiation, yet it effectively suppressed the Th1 and the Th17 cell differentiation. In conclusion, emodin prevents colorectal cancer via inhibiting cell growth, anti-inflammation, and adaptive immunity modulation, highlighting its potential in inflammation-associated colorectal cancer prevention.

Breast cancer remains a significant clinical challenge, with treatment failure and patient mortality primarily attributable to tumor metastasis. Daucosterol linoleate (DL) was previously isolated from sweet potato (Ipomoea batatas). Using HPLC analysis of ten commercial dried sweet potato products from different regions of China, DL was detected in all samples, with concentrations ranging from 1.24&#xa0;mg to 6.05&#xa0;mg per 100&#xa0;g, confirming its widespread presence in commercially processed sweet potato products. Pharmacokinetic analysis showed that DL exhibited a peak plasma concentration (Cmax) of 1452.28&#xa0;ng/mL, an elimination half-life (t1/2) of 11.14&#xa0;h, and a mean residence time (MRT) of 9.62&#xa0;h, supporting its potential for oral administration. DL significantly suppressed proliferation and migration of MCF-7, 4T1, and MDA-MB-231 cells in vitro and reduced lung metastasis in vivo. Proteomic analysis identified SCD1 as a key molecule mediating the effects of DL. Mechanistically, DL downregulated SCD1 to inhibit epithelial-mesenchymal transition (EMT), as evidenced by decreased expression of N-Cadherin, MMP2, Vimentin, and Snail, alongside increased E-Cadherin expression. Collectively, DL inhibits breast cancer metastasis by downregulating SCD1 and suppressing EMT, supporting its dual potential as a functional food ingredient and adjuvant therapeutic.

Antibiotic resistance that has been found among pathogenic bacteria has propelled the development of alternative antimicrobial agents. This study explores the antimicrobial properties of Terminalia catappa L. (Indian almond) leaf extracts as a natural antimicrobial agent in aquaculture, focusing on their effects on pathogenic bacteria and their ability to support beneficial nitrifying bacteria in recirculating aquaculture systems (RAS). Different extracts (Methanol, Ethanol and Aqueous) of T. catappa leaves were prepared and subjected to phytochemical analysis, revealing the presence of alkaloids, flavonoids, phenols, tannins, and terpenoids. The agar well diffusion test, Minimum inhibitory concentration (MIC), and Minimum bactericidal concentration test were used to determine antibacterial efficacy against pathogenic bacteria (Aeromonas caviae, A. veronii) and nitrifying bacteria (Rhodococcus rhodochrous, Bacillus oceanisediminis). The in vitro antibacterial assay results indicate that methanolic extracts at 25-250 mg/ml may inhibit pathogenic bacteria, but were less effective than other extracts against nitrifying bacteria. Electron microscopy (Field-Emission Scanning Electron Microscopy (FE-SEM) and Transmission Electron Microscopy (TEM)) was used to visualise structural damage in bacterial cells, including membrane rupture and cytoplasmic leakage, particularly in pathogenic strains. The methanol extract of Terminalia catappa leaves was found to have strong antibacterial activity, which could be attributed to the fact that it contained higher levels of phenolics, flavonoids, and other bioactive phytochemicals than aqueous extracts. The extract was more active in inhibiting pathogenic bacteria, with a relatively weaker effect on nitrifying bacteria, suggesting a selective antibacterial action in vitro. Future research should focus on in vivo validation and dose optimisation. The present study has shown that, in vitro, the extracts of Terminalia catappa leaves exhibit different antibacterial activity, with high levels of inhibition against pathogenic bacterial strains, compared with the action of selected heterotrophic nitrifying bacteria. Such findings provide preliminary data on selective antibacterial activity. However, the results are limited to in vitro confirmation and require in vivo validation before proceeding to further applications in aquaculture.

Heart failure (HF) is a high-mortality condition driven by cardiomyocyte death, and ferroptosis is a critical contributor to myocardial injury in this regard. Tanshinone IIA (Tan-IIA), a bioactive component from Salvia miltiorrhiza, has been shown to protect the heart, but its role in HF-related ferroptosis remains unclear. This study investigated whether Tan-IIA ameliorates HF by inhibiting ferroptosis and its underlying mechanism. We evaluated cardiac function, fibrosis, ferroptosis markers (such as ROS, Fe[Formula: see text], GSH, xCT, and GPX4), and Sirt1/p53 signaling using both a mouse model of HF induced by ligation of the left anterior descending (LAD) coronary artery and oxygen-glucose deprivation (OGD)-treated H9c2 cells. Direct binding of Tan-IIA to Sirt1 was verified by molecular docking, CETSA, and DARTS. Tan-IIA improved cardiac function, reduced fibrosis and inflammation, decreased ROS/Fe[Formula: see text], increased GSH, and upregulated xCT/GPX4 in vivo and in vitro. However, erastin reversed these effects. Tan-IIA upregulated Sirt1 and downregulated p53, while Sirt1 inhibition by EX527 abolished its cardioprotective and antiferroptotic actions. Tan-IIA ameliorates HF by inhibiting myocardial ferroptosis through the Sirt1/p53/GPX4 pathway thus in turn supports its potential clinical use in the treatment of HF.

This study aims to achieve a cross-cultural consolidation of the local and traditional knowledge in order to contribute to an understanding of these knowledge systems and to guide bioprospecting on Panax spp. Documentation-based taxonomic revision was performed to define the current accepted species in Panax. Historic uses of Panax spp. used in China was compiled using historical herbal literature. A cross-cultural ethnobotanical assembly was performed to compile the traditional uses of Panax spp. globally. With a network-based integration, the scattered local and traditional knowledge was consolidated and evaluated. Currently, the genus Panax comprises 14 accepted species, mainly distributed in East Asia and eastern North America, all of which are used locally as traditional food and/or medicine. Four species are recorded in Chinese historical herbals. Eight species and one variety are used by 25 of the Chinese ethnic minorities. Beyond China, there are ten species and two varieties used traditionally in 12 countries. General health promotion functions are frequently mentioned. In different biocultural backgrounds, the used species and usages varied greatly, and even the same species can be used differently. For the first time, this study archives a comprehensive understanding on the health benefits of global Panax spp. and provides solid evidence for their versatility in maintaining human health from the perspective of ethnobotany.

Frequently evolving into a highly immunosuppressive niche that facilitates tumor growth and metastasis, the tumor microenvironment (TME) serves as the primary site for interactions between tumor cells and the host immune system. Reversing this immunosuppressive state therefore represents a pivotal strategy for antitumor therapy. Natural products possess the distinct advantages of multi-targeted and multi-pathway mechanisms, as well as the capacity to enhance therapeutic efficacy while attenuating systemic toxicity. These characteristics perfectly align with the core principles of antitumor immunotherapy. Accumulating evidence demonstrates that natural products including Ganoderma lucidum polysaccharides, Astragalus polysaccharides, and Lycium barbarum polysaccharides, as well as bioactive single compounds such as curcumin, resveratrol, and bufalin, exert potent antitumor immunotherapeutic effects by remodeling the suppressive TME. Consequently, they are increasingly being utilized as synergists or adjuvants in advanced therapeutic modalities, which include adoptive immune cell therapy, cancer vaccines, and immune checkpoint inhibitors. In addition, the discovery of novel potential regulatory factors for tumor immunotherapy from natural products has attracted significant attention. This review provides a comprehensive overview of the latest progress on how natural products reshape the immunosuppressive landscape and enhance the systemic antitumor response. Ultimately, this review both underscores the immense translational potential of natural products in tumor immunotherapy and highlights critical directions for future standardized research.

CTRI/2025/06/088470 (https://ctri.nic.in).

Nephrolithiasis affects approximately 12% of the global population and is increasingly diagnosed at younger ages, highlighting the need for safer and more effective therapeutic options. Although Petroselinum crispum (P. crispum) is traditionally recognized for its diuretic properties, its specific curative efficacy against established calcium oxalate stones and its impact on the underlying oxidative stress pathways remain insufficiently characterized. Additionally, there is a critical need to validate the dose-dependent renoprotective mechanisms of the plant's extract to bridge the gap between ethnomedicinal use and clinical application. This study evaluated the renoprotective and antiurolithiatic potential of P. crispum ethanolic leaf extract in a well-established rat model of ethylene glycol-induced nephrolithiasis. Male albino rats received 1% ammonium chloride and 0.75% ethylene glycol for 28 days to induce lithiasis. From Day 15 onward, two groups were treated orally with P. crispum extract at 300 or 600&#x2009;mg/kg. Biochemical analyses of urine, serum, and kidney tissue, along with histopathological assessments, were performed. Ethylene glycol administration caused marked lithogenic changes, including decreased urine volume, elevated urinary pH, increased calcium excretion, oxidative stress, and impaired renal function. Moreover, it restored antioxidant status by elevating glutathione and reducing malondialdehyde and nitric oxide levels. Histopathological analysis confirmed a protective effect, with decreased crystal deposition and preservation of renal tubular architecture. These findings suggest that P. crispum exerts multimechanistic protective effects-diuretic, antioxidant, and nephroprotective-against urolithiasis. Further studies are warranted to elucidate the extract's molecular mechanisms and validate its clinical potential as a plant-based therapeutic agent for kidney stone prevention and management.

Sambucus nigra (SN) has been found to exhibit strong antioxidant properties and anti-inflammatory effects. In our study, we aimed to investigate the therapeutic effects of Sambucus nigra extracts (SNe) in interstitial cystitis, a condition in which inflammation plays a significant role in its pathophysiology. Thirty Wistar albino adult female rats were used in this study. All rats were housed at an average room temperature of 23&#xb0;C, with a 12-h light/dark cycle, and had ad libitum access to food. The rats were divided into three groups: Group 1 (n = 10): Control (sham) group, Group 2 (n = 10): Interstitial cystitis group, and Group 3 (n = 10): Treatment group. Rats in Group 3 were administered oral Sambucus nigra extract at a dose of 0.040 g/kg every other day for a total of 8 weeks. Bladder tissues were examined both histologically and immunohistochemically, with a focus on mast cells and the presence of Interleukin-6 (IL-6), Interleukin-8 (IL-8), Vascular Endothelial Growth Factor (VEGF), and Tumor Necrosis Factor-&#x3b1; (TNF-&#x3b1;). The findings of chronic inflammation were striking in the bladder sections of the interstitial cystitis group. In the treatment group, regenerating transitional epithelium, a compact appearance in the lamina propria, and a decrease in inflammatory cells and mast cells were observed. While significant improvements were noted in IL-8, TNF-&#x3b1;, and mast cell counts, there was a reduction in IL-6 and VEGF levels, although this reduction was not statistically significant. Sambucus nigra, significantly reduces TNF-&#x3b1;, Mast cell, VEGF, IL-6, and IL-8 levels in interstitial cystitis (IC) bladder tissue. It provides recovery in damaged bladder epithelium, smooth muscle, and basal membrane. SN attracts attention as an important agent due to its effects in the treatment of IC.

Background: Oromucosal films are thin polymeric dosage forms designed to hydrate rapidly in the oral cavity and enable local or systemic drug delivery. Their performance depends on coupled processes including wetting, swelling, polymer relaxation, matrix softening, and structural failure. Because these phenomena depend strongly on the formulation composition and polymer-network organization, a mechanistic framework linking conventional characterization data to film performance is needed. This study aimed to develop a Madelung-type multifractal swelling-disintegration-release-readiness model for chitosan/hydroxypropyl methylcellulose (HPMC) films and to examine its relevance using a twelve-formulation experimental series. Methods: Twelve films based on chitosan (film-forming polysaccharide), HPMC K-4M (hydrophilic swelling polymer), glycerin (plasticizer), and starch (disintegrant) were prepared via solvent casting. The films were characterized for loss on drying, surface pH, mass and thickness uniformity, wetting time, swelling behavior, structural-disintegration onset, elongation response, rupture resistance, folding endurance, and surface roughness. The proposed model described water uptake, swelling-front motion, matrix integrity, local release-readiness activation, and hydration-induced loading as coupled fields across the film thickness. Results: Formulation markedly influenced hydration behavior, mechanical performance, structural stability, and surface morphology. Films F2 and F7 emerged as the most promising complementary unloaded matrix platforms for future active-compound incorporation and experimental release evaluation. F2 behaved as a high-swelling, mechanically stable starch-free matrix, whereas F7 combined faster wetting, starch-assisted structural destabilization, and favorable flexibility. Conclusions: This framework provides a quantitative link between empirical film characterization and formulation-level mechanistic interpretation. It translates conventional characterization parameters into descriptors related to the apparent water penetration, swelling capacity, matrix-failure tendency, mechanical suitability, and structural heterogeneity. The present results support candidate selection for future Active Pharmaceutical Ingredient-loaded studies but do not constitute validation of drug-release kinetics.